Original language | English |
---|---|
Number of pages | 0 |
Journal | Journal of Hepatology |
Volume | 0 |
Issue number | 0 |
Early online date | 30 Mar 2022 |
DOIs | |
Publication status | Published - 30 Mar 2022 |
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis
Christopher L. Bowlus*, Michael R. Galambos, Richard J. Aspinall, Gideon M. Hirschfield, David E.J. Jones, Yvonne Dörffel, Stuart C. Gordon, Stephen A. Harrison, Andreas E. Kremer, Marlyn J. Mayo, Paul J. Thuluvath, Cynthia Levy, Mark G. Swain, Guy W. Neff, David A. Sheridan, Carmen M. Stanca, Christoph P. Berg, Aparna Goel, Mitchell L. Shiffman, John M. Vierling
*Corresponding author for this work
- University of California at Davis
- Piedmont Atlanta Hospital
- Portsmouth Hospitals University NHS Trust
- University Health Network University of Toronto
- Newcastle University
- Charité Universitätsmedizin Berlin
- Henry Ford Health System
- Pinnacle Clinical Research
- University of Oxford
- Friedrich-Alexander University Erlangen-Nürnberg
- University of Zurich
- University of Texas Southwestern Medical Center
- Mercy Medical Center Baltimore
- University of Maryland, Baltimore
- University of Miami
- University of Calgary
- LLC
- University Hospitals Plymouth NHS Trust
- New York University
- University of Tübingen
- Stanford University
- Liver Institute of Virginia
- Baylor College of Medicine
- Inc.
Research output: Contribution to journal › Article › peer-review
15
Downloads
(Pure)